Allergan PLC. (NYSE:AGN)‘s stock had its “buy” rating restated by research analysts at Royal Bank Of Canada in a research report issued to clients and investors on Wednesday. They presently have a $285.00 price target on the stock. Royal Bank Of Canada’s target price would indicate a potential upside of 25.04% from the stock’s current price.

Other equities research analysts have also recently issued research reports about the company. Vetr raised Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 target price on the stock in a report on Monday, June 26th. UBS AG reaffirmed a “buy” rating and issued a $275.00 price target on shares of Allergan PLC. in a report on Monday, May 15th. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $280.00 price target (up previously from $270.00) on shares of Allergan PLC. in a report on Wednesday, August 9th. Goldman Sachs Group, Inc. (The) cut Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 price target on the stock. in a report on Wednesday, May 10th. Finally, Deutsche Bank AG reaffirmed a “buy” rating and issued a $273.00 price target (up previously from $265.00) on shares of Allergan PLC. in a report on Monday, July 17th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $275.49.

Shares of Allergan PLC. (NYSE:AGN) opened at 227.93 on Wednesday. Allergan PLC. has a 12-month low of $184.50 and a 12-month high of $256.80. The firm has a market cap of $76.20 billion, a PE ratio of 6.94 and a beta of 1.18. The company has a 50 day moving average price of $236.06 and a 200-day moving average price of $237.31.

Allergan PLC. (NYSE:AGN) last announced its earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The firm had revenue of $4.01 billion for the quarter, compared to analysts’ expectations of $3.95 billion. During the same quarter in the previous year, the company earned $3.35 earnings per share. The firm’s quarterly revenue was up 8.8% compared to the same quarter last year. Analysts expect that Allergan PLC. will post $16.27 EPS for the current year.

WARNING: This news story was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://theolympiareport.com/2017/09/08/allergan-plc-agn-stock-rating-reaffirmed-by-royal-bank-of-canada.html.

Institutional investors have recently added to or reduced their stakes in the business. Howard Hughes Medical Institute acquired a new position in Allergan PLC. during the 2nd quarter worth $103,000. Enterprise Financial Services Corp raised its position in shares of Allergan PLC. by 62.7% during the first quarter. Enterprise Financial Services Corp now owns 462 shares of the company’s stock valued at $110,000 after buying an additional 178 shares during the last quarter. Jacobi Capital Management LLC raised its position in shares of Allergan PLC. by 4.9% during the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock valued at $112,000 after buying an additional 22 shares during the last quarter. JNBA Financial Advisors raised its position in shares of Allergan PLC. by 2.5% during the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock valued at $116,000 after buying an additional 12 shares during the last quarter. Finally, Massey Quick & Co. LLC raised its position in shares of Allergan PLC. by 334.8% during the second quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock valued at $122,000 after buying an additional 385 shares during the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Analyst Recommendations for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.